Adjuvant temozolomide: how long and how much?
- 1 May 2008
- journal article
- Published by Taylor & Francis Ltd in Expert Review of Anticancer Therapy
- Vol. 8 (5), 663-665
- https://doi.org/10.1586/14737140.8.5.663
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent GliomaJournal of Clinical Oncology, 2007
- Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastomaBritish Journal of Cancer, 2007
- Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)British Journal of Cancer, 2006
- Mathematical Modelling of Survival of Glioblastoma Patients Suggests a Role for Radiotherapy Dose Escalation and Predicts Poorer Outcome After Delay to Start TreatmentClinical Oncology, 2006
- Salvage temozolomide for prior temozolomide respondersCancer, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- Repair of O6-alkylguanine by alkyltransferasesMutation Research, 2000